Information Links
Previous Issues Volume 5, Issue 1 - 2020
Inflammatory Bowel Disease with Crohn’s-like Phenotype in Patient with Common Variable Immunodeficiency: A Case Report
Aya Hammami*, Raida Harbi, Amani Hassine, Nour Elleuch, Wafa Dahmani, Wafa Ben Ameur, Hanen Jaziri, Ali Jmaa
University of Sousse, Faculty of medecine of Sousse, Department of Gastroenterology, University Hospital of Sahloul- Sousse, Tunisia
*Corresponding author: Aya Hammami, University of Sousse, Faculty of medecine of Sousse, Department of Gastroenterology, University Hospital of Sahloul- Sousse, Tunisia, Tel: +21654868578; E-mail: [email protected]
Received Date: December 07, 2020
Published Date: December 31, 2020
Copyright: Hammami A, et al. (2020)
Citation: Hammami A, et al. (2020). Inflammatory bowel disease with Crohn’s-like phenotype in patient with Common Variable immunodeficiency: A case report. Mathews J Gastroenterol Hepatol. (5)1:14.
ABSTRACT
Background: Common variable immunodeficiency (CVID) is the most prevalent type of primary immunodeficiency syndrome in adults. It is characterized by reduced levels of serum immunoglobulins responsible for recurrent bacterial infections and increased susceptibility to inflammatory affections, particularly autoimmune diseases, such as inflammatory bowel disease.
Case summary: Herein, we present the case of a 32-year-old patient with past medical history of recurrent rhinopulmonary infections, who presented with digestive symptoms consisting of chronic diarrhea, associated to abdominal pain, and fever, being diagnosed of Crohn-like disease associated to CVID. Our patient was treated with adalimumab and achieved favorable clinical response with no adverse reaction or increased susceptibility to infections. He has been in clinical remission for 2 years. The treatment with immunomodulators in this immunodeficiency status is a real therapeutic challenge. To the best of our knowledge, it is the first case reported in Tunisia.
Conclusions: We described this case to share our experience in the management of Crohn’s-like disease associated to common variable immune deficiency and to support that anti-TNF alpha could be a safe and efficient therapeutic option in similar cases.
